rg2833 has been researched along with Disease-Models--Animal* in 2 studies
2 other study(ies) available for rg2833 and Disease-Models--Animal
| Article | Year |
|---|---|
Impaired inhibitory GABAergic synaptic transmission and transcription studied in single neurons by Patch-seq in Huntington's disease.
Topics: Animals; Benzamides; Corpus Striatum; Disease Models, Animal; GABA Agents; Gene Expression; Huntingtin Protein; Huntington Disease; Mice; Mice, Inbred C57BL; Neurons; Sequence Analysis, RNA; Synaptic Transmission; Transcriptome | 2021 |
Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model.
Friedreich's ataxia (FRDA), the most common recessive ataxia in Caucasians, is due to severely reduced levels of frataxin, a highly conserved protein, that result from a large GAA triplet repeat expansion within the first intron of the frataxin gene (FXN). Typical marks of heterochromatin are found near the expanded GAA repeat in FRDA patient cells and mouse models. Histone deacetylase inhibitors (HDACIs) with a pimelic diphenylamide structure and HDAC3 specificity can decondense the chromatin structure at the FXN gene and restore frataxin levels in cells from FRDA patients and in a GAA repeat based FRDA mouse model, KIKI, providing an appealing approach for FRDA therapeutics.. In an effort to further improve the pharmacological profile of pimelic diphenylamide HDACIs as potential therapeutics for FRDA, we synthesized additional compounds with this basic structure and screened them for HDAC3 specificity. We characterized two of these compounds, 136 and 109, in FRDA patients' peripheral blood lymphocytes and in the KIKI mouse model. We tested their ability to upregulate frataxin at a range of concentrations in order to determine a minimal effective dose. We then determined in both systems the duration of effect of these drugs on frataxin mRNA and protein, and on total and local histone acetylation. The effects of these compounds exceeded the time of direct exposure in both systems.. Our results support the pre-clinical development of a therapeutic approach based on pimelic diphenylamide HDACIs for FRDA and provide information for the design of future human trials of these drugs, suggesting an intermittent administration of the drug. Topics: Animals; Base Sequence; Disease Models, Animal; DNA Primers; Frataxin; Friedreich Ataxia; Histone Deacetylase Inhibitors; Humans; Iron-Binding Proteins; Mice; Models, Animal; Pimelic Acids; Polymerase Chain Reaction; Up-Regulation | 2010 |